Pharmacological inhibition of PPARγ increases osteoblastogenesis and bone mass in male C57BL/6 mice

Journal of Bone and Mineral Research

Volumn 28, Issue 3, 2013, Pages 639-648

  Duque, Gustavo ^a   Li, Wei ^a   Vidal, Christopher ^a   Bermeo, Sandra ^a   Rivas, Daniel ^b   Henderson, Janet ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

ADIPOGENESIS; AGING; OSTEOBLASTOGENESIS; OSTEOPOROSIS; PPAR

Indexed keywords

2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; CALCIUM ION; GLUCOSE; PARATHYROID HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MARROW; BONE MASS; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; LYMPHOCYTE TRANSFORMATION; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OBESITY; OSSIFICATION; OSTEOBLASTOGENESIS; OSTEOCLAST; OSTEOID; OSTEOLYSIS; PHENOTYPE; PROTEIN EXPRESSION;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOTTING, WESTERN; BONE AND BONES; EPOXY COMPOUNDS; MALE; MICE; MICE, INBRED C57BL; ORGAN SIZE; OSTEOBLASTS; PPAR GAMMA; TOMOGRAPHY, X-RAY COMPUTED; VITAMIN D;

EID: 84873948364     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1782     Document Type: Article

References (25)

1. Marie PJ, Kassem M., Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol. 2011; 165: 1-10.
2. Leder B., Gonadal steroids and bone metabolism in men. Curr Opin Endocrinol Diabetes Obes. 2007; 14: 241-6.
3. Khosla S, Westendorf JJ, Oursler MJ., Building bone to reverse osteoporosis and repair fractures. J Clin Invest. 2008; 118: 421-8.
4. Lane NE, Silverman SL., Anabolic therapies. Curr Osteoporos Rep. 2010; 8: 23-7.
5. Wren TA, Chung SA, Dorey FJ, Bluml S, Adams GB, Gilsanz V., Bone marrow fat is inversely related to cortical bone in young and old subjects. J Clin Endocrinol Metab. 2011; 96: 782-6.
6. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME., Playing with bone and fat. J Cell Biochem. 2006; 98: 251-66.
7. Lecka-Czernik B, Rosen CJ, Kawai M., Skeletal aging and the adipocyte program: new insights from an "old" molecule. Cell Cycle. 2010; 9: 3648-54.
8. Liu W, Toyosawa S, Furuichi T, Kanatani N, Yoshida C, Liu Y, Himeno M, Narai S, Yamaguchi A, Komori T., Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol. 2001; 155: 157-66.
9. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H., PPARgamma enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004; 113: 846-55.
10. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM., A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem. 2000; 275: 1873-7.
11. Botolin S, McCabe LR., Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol. 2006; 209: 967-76.
12. Duque G, Macoritto M, Dion N, Ste-Marie LG, Kremer R., 1 25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). Am J Physiol Endocrinol Metab. 2005; 288: E723-30.
13. Li W, Yeo LS, Vidal C, McCorquodale T, Herrmann M, Fatkin D, Duque G., Decreased bone formation and osteopenia in lamin a/c-deficient mice. PLoS One. 2011; 6: e19313.
14. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25: 1468-86.
15. Parfitt AM, Drezner MR, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR., Bone histomorphometry: standardization of nomenclature, symbols and units. J Bone Miner Res. 1987; 2: 595-610.
16. Elbaz A, Rivas D, Duque G., Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. Biogerontology. 2009; 10: 747-55.
17. Duque G, Macoritto M, Kremer R., 1 25(OH)2D3 inhibits bone marrow adipogenesis in senescence accelerated mice (SAM-P/6) by decreasing the expression of peroxisome proliferator-activated receptor gamma 2 (PPARgamma2). Exp Gerontol. 2004; 39: 333-8.
18. Rickard DJ, Wang FL, Rodriguez-Rojas AM, Wu Z, Trice WJ, Hoffman SJ, Votta B, Stroup GB, Kumar S, Nuttall ME., Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone. 2006; 39: 1361-72.
19. Duque G, Huang DC, Dion N, Macoritto M, Rivas D, Li W, Yang XF, Li J, Lian J, Marino FT, Barralet J, Lascau V, Deschênes C, Ste-Marie LG, Kremer R., Interferon-γ plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J Bone Miner Res. 2011; 26: 1472-83.
20. Vidal C, Bermeo S, Li W, Huang D, Kremer R, Duque G., Interferon gamma inhibits adipogenesis and prevents marrow fat infiltration in oophorectomized mice. Stem Cells. 2012; 30: 1042-8.
21. Fournier C, Perrier A, Thomas M, Laroche N, Dumas V, Rattner A, Vico L, Guignandon A., Reduction by strontium of the bone marrow adiposity in mice and repression of the adipogenic commitment of multipotent C3H10T1/2cells. Bone. 2012; 50: 499-509.
22. Pei L, Tontonoz P., Fat's loss is bone's gain. J Clin Invest. 2004; 113: 805-6.
23. Yu WH, Li FG, Chen XY, Li JT, Wu YH, Huang LH, Wang Z, Li P, Wang T, Lahn BT, Xiang AP., PPARγ suppression inhibits adipogenesis but does not promote osteogenesis of human mesenchymal stem cells. Int J Biochem Cell Biol. 2012; 44: 377-84.
24. Ferguson VL, Ayers RA, Bateman TA, Simske SJ., Bone development and age-related bone loss in male C57BL/6J mice. Bone. 2003; 33: 387-98.
25. -/- mice. Hum Mol Genet. 2004; 13: 271-84.